87 related articles for article (PubMed ID: 26527820)
21. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
Zhao Q; Lu H; Schols D; De Clercq E; Jiang S
AIDS Res Hum Retroviruses; 2003 Nov; 19(11):947-55. PubMed ID: 14678601
[TBL] [Abstract][Full Text] [Related]
22. Development of Triazoles and Triazolium Salts Based on AZT and Their Anti-Viral Activity against HIV-1.
de Alencar DM; Gonçalves J; Vieira A; Cerqueira SA; Sebastião C; Leitão MIPS; Francescato G; Antenori P; Soares H; Petronilho A
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771129
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity.
Curreli F; Belov DS; Ramesh RR; Patel N; Altieri A; Kurkin AV; Debnath AK
Bioorg Med Chem; 2016 Nov; 24(22):5988-6003. PubMed ID: 27707628
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, lipophilicity and anti-HIV activity of a new brominated analog of zidovudine.
Motura M; Salomón H; Moroni G; Wainberg M; Briñón MC
Nucleosides Nucleotides; 1999 Mar; 18(3):337-51. PubMed ID: 10358940
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
[TBL] [Abstract][Full Text] [Related]
27. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
28. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
29. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
[TBL] [Abstract][Full Text] [Related]
30. Abortive infection in HeLaCD4 cells by a primary HIV type 1 isolate: implications for differential host cell tropism.
Smyth RJ; Yi Y; Kim FM; Collman RG
AIDS Res Hum Retroviruses; 1997 Jun; 13(9):759-69. PubMed ID: 9171220
[TBL] [Abstract][Full Text] [Related]
31. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
Albright AV; Erickson-Viitanen S; O'Connor M; Frank I; Rayner MM; González-Scarano F
AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1527-37. PubMed ID: 11054266
[TBL] [Abstract][Full Text] [Related]
32. Superiority of the S,S conformation in diverse pharmacological processes: Intestinal transport and entry inhibition activity of novel anti-HIV drug lead.
Fanous J; Swed A; Joubran S; Hurevich M; Britan-Rosich E; Kotler M; Gilon C; Hoffman A
Int J Pharm; 2015 Nov; 495(2):660-3. PubMed ID: 26392249
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of novel SATE derivatives of acyclic isocytosine and 9-deazaadenine C-nucleosides.
Liu LJ; Hong JH
Nucleosides Nucleotides Nucleic Acids; 2010 Mar; 29(3):257-66. PubMed ID: 20408056
[TBL] [Abstract][Full Text] [Related]
34. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
Figueiredo A; Moore KL; Mak J; Sluis-Cremer N; de Bethune MP; Tachedjian G
PLoS Pathog; 2006 Nov; 2(11):e119. PubMed ID: 17096588
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives.
Sakakibara N; Balboni G; Congiu C; Onnis V; Demizu Y; Misawa T; Kurihara M; Kato Y; Maruyama T; Toyama M; Okamoto M; Baba M
Antivir Chem Chemother; 2015 Apr; 24(2):62-71. PubMed ID: 26514833
[TBL] [Abstract][Full Text] [Related]
36. Cell-penetrating, dimeric α-helical peptides: nanomolar inhibitors of HIV-1 transcription.
Jang S; Hyun S; Kim S; Lee S; Lee IS; Baba M; Lee Y; Yu J
Angew Chem Int Ed Engl; 2014 Sep; 53(38):10086-9. PubMed ID: 25056130
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Meng Q; Chen X; Kang D; Huang B; Li W; Zhan P; Daelemans D; De Clercq E; Pannecouque C; Liu X
Eur J Med Chem; 2016 Jun; 115():53-62. PubMed ID: 26994843
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
Danel K; Larsen LM; Pedersen EB; Sanna G; La Colla P; Loddo R
Bioorg Med Chem; 2008 Jan; 16(1):511-7. PubMed ID: 17904371
[TBL] [Abstract][Full Text] [Related]
39. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells.
Rocancourt D; Bonnerot C; Jouin H; Emerman M; Nicolas JF
J Virol; 1990 Jun; 64(6):2660-8. PubMed ID: 2110596
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of zidovudine derivatives with anti-HIV-1 and antibacterial activities.
Senthilkumar P; Long J; Swetha R; Shruthi V; Wang RR; Preethi S; Yogeeswari P; Zheng YT; Sriram D
Nucleosides Nucleotides Nucleic Acids; 2009 Feb; 28(2):89-102. PubMed ID: 19219739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
